ES2187503T3 - Esteroides angiostaticos. - Google Patents

Esteroides angiostaticos.

Info

Publication number
ES2187503T3
ES2187503T3 ES93900609T ES93900609T ES2187503T3 ES 2187503 T3 ES2187503 T3 ES 2187503T3 ES 93900609 T ES93900609 T ES 93900609T ES 93900609 T ES93900609 T ES 93900609T ES 2187503 T3 ES2187503 T3 ES 2187503T3
Authority
ES
Spain
Prior art keywords
angiostatic steroids
neovascularization
control
hypertension
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93900609T
Other languages
English (en)
Inventor
Abbot F Clark
Raymond E Conrow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/941,485 external-priority patent/US5371078A/en
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Application granted granted Critical
Publication of ES2187503T3 publication Critical patent/ES2187503T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0027—Azides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE DESCRIBEN UNOS ESTEROIDES ANGIOSTATICOS PARA UTILIZAR EN EL CONTROL DE NEOVASCULARIZACION E HIPERTENSION OCULAR. SE DESCRIBEN TAMBIEN LAS COMPOSICIONES FARMACOLOGICAS DE LOS ESTEROIDES ANGIOSTATICOS Y LOS METODOS PARA SU USO EN NEOVASCULARIZACION E HIPERTENSION OCULAR QUE INCLUYEN EL CONTROL DE LA HIPERTENSION OCULAR ASOCIADA CON EL GLAUCOMA DE ANGULO ABIERTO PRIMARIO. ADEMAS, SE DESCRIBE LA COMBINACION DE LOS COMPONENTES CON GLUCOCORTICOIDES PARA LA PREVENCION DE ELEVADA PRESION INTRAOCULAR DURANTE EL TRATAMIENTO DE LA INFLAMACION.
ES93900609T 1991-11-22 1992-11-23 Esteroides angiostaticos. Expired - Lifetime ES2187503T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79616991A 1991-11-22 1991-11-22
US89244892A 1992-06-02 1992-06-02
US07/941,485 US5371078A (en) 1988-10-31 1992-09-08 Angiostatic steroids and methods and compositions for controlling ocular hypertension

Publications (1)

Publication Number Publication Date
ES2187503T3 true ES2187503T3 (es) 2003-06-16

Family

ID=27419924

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93900609T Expired - Lifetime ES2187503T3 (es) 1991-11-22 1992-11-23 Esteroides angiostaticos.

Country Status (10)

Country Link
EP (4) EP1236469A3 (es)
JP (1) JP3378245B2 (es)
AT (1) ATE232540T1 (es)
AU (1) AU678961B2 (es)
CA (4) CA2425846A1 (es)
DE (1) DE69232925T2 (es)
DK (1) DK0614463T3 (es)
ES (1) ES2187503T3 (es)
HK (3) HK1046370A1 (es)
WO (1) WO1993010141A2 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990099A (en) * 1988-10-31 1999-11-23 Alcon Laboratories, Inc. Angiostatic agents and methods and compositions for controlling ocular hypertension
US5969168A (en) * 1991-01-07 1999-10-19 Pherin Corporation Androstanes for inducing hypothalamic effects
DE4311987A1 (de) * 1993-04-07 1994-10-13 Schering Ag Neue Glucocorticoide
EP1340502A3 (en) * 1993-06-15 2004-01-21 Pherin Corporation Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US5646136A (en) * 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
AU1970197A (en) * 1996-05-09 1997-11-26 Alcon Laboratories, Inc. Use of steroid compounds to prevent non-cancerous tissue growth
EP1806131A3 (en) 1996-07-22 2007-08-01 Renovo Limited Use of sex steroid function modulators to treat wounds and fibrotic disorders
AU1935501A (en) * 1999-12-09 2001-06-18 Alcon Universal Limited Id protein inhibitors for treating ocular diseases
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
AU1770901A (en) * 2000-11-16 2002-05-27 Alcon Lab Inc Combination therapy for lowering and controlling intraocular pressure
AU2002236495B2 (en) 2000-11-29 2006-05-11 Allergan, Inc. Intraocular implants for preventing transplant rejection in the eye
CN100353947C (zh) * 2001-03-28 2007-12-12 参天制药株式会社 以甾体为有效成分的视网膜和脉络膜疾病治疗剂
US20030119800A1 (en) * 2001-06-18 2003-06-26 Manolagas Stavros C. Bone anabolic compounds and methods of use
US20040214806A1 (en) 2002-09-03 2004-10-28 Iok-Hou Pang Use of non-feminizing estrogens as retinoprotective agents for the treatment of glaucoma
TWI320712B (en) * 2001-09-05 2010-02-21 Alcon Inc The use of non-feminizing estrogens as retinoprotective agents for the treatment of glaucoma
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US8023950B2 (en) 2003-02-18 2011-09-20 Qualcomm Incorporated Systems and methods for using selectable frame durations in a wireless communication system
US8081598B2 (en) 2003-02-18 2011-12-20 Qualcomm Incorporated Outer-loop power control for wireless communication systems
US7155236B2 (en) 2003-02-18 2006-12-26 Qualcomm Incorporated Scheduled and autonomous transmission and acknowledgement
US8391249B2 (en) 2003-02-18 2013-03-05 Qualcomm Incorporated Code division multiplexing commands on a code division multiplexed channel
US20040160922A1 (en) 2003-02-18 2004-08-19 Sanjiv Nanda Method and apparatus for controlling data rate of a reverse link in a communication system
US7660282B2 (en) 2003-02-18 2010-02-09 Qualcomm Incorporated Congestion control in a wireless data network
GB0304927D0 (en) 2003-03-04 2003-04-09 Resolution Chemicals Ltd Process for the production of tibolone
US8705588B2 (en) 2003-03-06 2014-04-22 Qualcomm Incorporated Systems and methods for using code space in spread-spectrum communications
US7215930B2 (en) 2003-03-06 2007-05-08 Qualcomm, Incorporated Method and apparatus for providing uplink signal-to-noise ratio (SNR) estimation in a wireless communication
EP2301549A1 (en) * 2003-04-18 2011-03-30 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
WO2004093882A1 (ja) * 2003-04-18 2004-11-04 Advanced Medicine Research Institute 眼に適用する疾患治療剤
US8477592B2 (en) 2003-05-14 2013-07-02 Qualcomm Incorporated Interference and noise estimation in an OFDM system
RU2376728C2 (ru) * 2003-08-05 2009-12-20 Квэлкомм Инкорпорейтед Расширенный канал подтверждения и управления скоростью
US8489949B2 (en) 2003-08-05 2013-07-16 Qualcomm Incorporated Combining grant, acknowledgement, and rate control commands
US7315527B2 (en) * 2003-08-05 2008-01-01 Qualcomm Incorporated Extended acknowledgement and rate control channel
US20050239760A1 (en) * 2004-04-23 2005-10-27 Alcon, Inc. Angiostatic agents and methods and compositions for controlling ocular hypertension
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
JP2008504329A (ja) * 2004-06-29 2008-02-14 ヤド テクノロジーズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 脂質ラフト内の病理プロセスに関係する障害を治療するためのステロイド由来の医薬組成物の使用
CN101282646B (zh) 2005-07-12 2013-03-27 Dmi生物科学公司 治疗疾病的方法和产品
JP5780521B2 (ja) 2008-05-28 2015-09-16 リベラジェン・バイオファーマ・インコーポレイテッドＲｅｖｅｒａＧｅｎ ＢｉｏＰｈａｒｍａ，Ｉｎｃ． 疾患を治療するための、ＮＦ−κＢの非ホルモン性ステロイド調節因子
ES2523769T3 (es) 2009-06-22 2014-12-01 Ampio Pharmaceuticals, Inc. Procedimiento de tratamiento de enfermedades
WO2011127048A2 (en) 2010-04-05 2011-10-13 Validus Biopharma NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE
EP2934546A4 (en) 2012-12-19 2016-06-22 Ampio Pharmaceuticals Inc METHOD OF DISEASE TREATMENT
US10617723B2 (en) 2013-03-29 2020-04-14 Biomed Valley Discoveries, Inc. C. novyi for the treatment of solid tumors in humans
US11033621B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells
AU2016211246B2 (en) 2015-01-30 2020-08-27 Biomed Valley Discoveries, Inc. Crystalline forms of C21H22CI2N4O2
JP7180977B2 (ja) 2015-01-30 2022-11-30 バイオメッド バレー ディスカバリーズ，インコーポレイティド 結晶性Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２マロン酸塩
WO2017004205A1 (en) 2015-06-29 2017-01-05 Reveragen Biopharma, Inc. NON-HORMONAL STEROID MODULATORS OF NF-κB FOR TREATMENT OF DISEASE
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB790452A (en) * 1955-04-01 1958-02-12 Upjohn Co Steroids and the preparation thereof
US3658856A (en) * 1969-09-02 1972-04-25 Syntex Corp Process for preparing useful 17alpha-hydroxy-20-keto-21-acyloxy pregnanes
US4041055A (en) * 1975-11-17 1977-08-09 The Upjohn Company Process for the preparation of 17α-hydroxyprogesterones and corticoids from androstenes
US4357279A (en) * 1981-05-18 1982-11-02 The Upjohn Company Preparation of corticoids from 17-keto steroids
US4342702A (en) * 1981-05-18 1982-08-03 The Upjohn Company Metallated halogenated acetylene corticoid synthesis
US4617299A (en) * 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4600538A (en) * 1984-08-02 1986-07-15 The Upjohn Company Corticosteroids from 17-keto steroids via 20-cyano-Δ17 (20)-pregnanes
US4812448A (en) * 1984-10-22 1989-03-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
JP2545522B2 (ja) * 1985-10-23 1996-10-23 アルコン・ラボラトーリーズ，インコーポレイテッド テトラヒドロ脈管形成抑制ステロイド
US4975537A (en) * 1985-10-23 1990-12-04 The Upjohn Company Δ9(11) -angiostatic steroids
US4686214A (en) * 1985-10-30 1987-08-11 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
US5036048A (en) * 1986-03-07 1991-07-30 Schering Corporation Angiotensin II receptor blockers as antiglaucoma agents
US4863912A (en) * 1986-05-19 1989-09-05 New York Medical College Use of tetrahydrocortisol in glaucoma therapy
DE3878463T2 (de) * 1987-08-14 1993-06-24 Upjohn Co Verfahren zur 9-alpha-dehalogenierung von 9-alpha-steroiden.
US4876250A (en) * 1988-10-31 1989-10-24 Alcon Laboratories, Inc. Methods for controlling ocular hypertension with angiostatic steroids
EP0477195A1 (en) * 1989-06-16 1992-04-01 The Upjohn Company Suramin type compounds and angiostatic steroids to inhibit angiogenesis
EP0489779B1 (en) * 1989-08-28 1998-01-28 Alcon Laboratories, Inc. Ophthalmic composition
JP2985007B2 (ja) * 1990-02-09 1999-11-29 武田薬品工業株式会社 血管新生阻害剤
WO1991019731A1 (en) * 1990-06-11 1991-12-26 The Upjohn Company Steroids which inhibit angiogenesis

Also Published As

Publication number Publication date
HK1046371A1 (en) 2003-01-10
EP1236471A2 (en) 2002-09-04
HK1046369A1 (en) 2003-01-10
EP0614463B1 (en) 2003-02-12
HK1046370A1 (en) 2003-01-10
CA2425841C (en) 2006-01-10
JPH07501081A (ja) 1995-02-02
DK0614463T3 (da) 2003-03-31
CA2425841A1 (en) 1993-05-27
EP1236470A2 (en) 2002-09-04
EP1236471A3 (en) 2004-12-15
CA2123405A1 (en) 1993-05-27
DE69232925T2 (de) 2003-06-18
ATE232540T1 (de) 2003-02-15
WO1993010141A3 (en) 1993-09-02
CA2425846A1 (en) 1993-05-27
AU678961B2 (en) 1997-06-19
EP1236469A3 (en) 2004-09-01
CA2425849A1 (en) 1993-05-27
EP1236470A3 (en) 2004-09-01
CA2425849C (en) 2007-02-27
JP3378245B2 (ja) 2003-02-17
EP1236469A2 (en) 2002-09-04
AU3223593A (en) 1993-06-15
CA2123405C (en) 2008-01-15
DE69232925D1 (de) 2003-03-20
HK1012638A1 (en) 1999-08-06
EP0614463A1 (en) 1994-09-14
WO1993010141A2 (en) 1993-05-27

Similar Documents

Publication Publication Date Title
ES2187503T3 (es) Esteroides angiostaticos.
DK542989D0 (da) Praeparat til bekaempelse af ocular hypertension
DK1920764T4 (da) Fluprostenolisopropylester til anvendelse ved behandling af glaukom og okulær hypertension
ES2062102T3 (es) Derivados de prostaglandinas para el tratamiento de glaucoma o hipertension ocular.
MX9400037A (es) Composicion oftalmica para el tratamiento de glaucoma e hipertension ocular.
GB1076560A (en) Improvements in or relating to photocoagulation apparatus
MX9204381A (es) Metodo para tratar inflamacion ocular
BR9811012A (pt) "uso de um composto".
DE69521620D1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
PT868186E (pt) Utilizacao de certos compostos de isoquinolinossulfonilo para tratamento de glaucoma e isquemia ocular
BR0004635A (pt) Dispositivo para cirurgia de córnea fotorrefrativa em defeitos de visão de uma ordem superior
ES2154262T3 (es) Uso de compuestos macrolidos para enfermedades oculares.
ES2155478T3 (es) Uso de oligosacaridos en la prevencion y tratamiento del envejecimiento de los tejidos.
ATE216889T1 (de) Anwendung von prostagrandin-analogen für die behandlung von glaukome und okuläre hypertension
ES2107806T3 (es) Nuevos esteroides.
ATE326972T1 (de) Heilende zusammensetzung für intraokulare hypertension oder glaukom
CA2064478A1 (en) Ophthalmic composition
ES2139602T3 (es) Composiciones oculares que contienen esteroides y su utilizacion para el tratamiento del glaucoma.
BR9407359A (pt) Dispositivo para alterar as propriedades refrativas corneais
PT1021184E (pt) Utilizacao de flunarizina para o tratamento topico da hipertensao ocular
ES2059058T3 (es) Combinacion sinergica para uso oftalmico.
Nitikarun Ophthalmic Injuries from Spitting Cobra Venom: Three Case Reports
ES2120503T3 (es) Compuestos antiinflamatorios para uso oftalmico.
MX9304479A (es) Derivados de lectina de bauhinia purpurea y su uso como larvicidas.
CO4340602A1 (es) Estructura perfeccionada para gafas protectoras